Online inquiry

IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3605MR)

This product GTTS-WQ3605MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets LYPD3 gene. The antibody can be applied in Neoplasms research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_014400.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 27076
UniProt ID O95274
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3605MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8846MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ13007MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PEG-G-CSF
GTTS-WQ11080MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MCS-110
GTTS-WQ4295MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BIIB-054
GTTS-WQ12183MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MORAb-022
GTTS-WQ12783MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ4595MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986015
GTTS-WQ13288MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06523435
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW